LindsayBKilburnMD
Pediatric Hematology & Oncology • Washington, DCPediatric Neuro-Oncology
Attending physician in Neuro-Oncology and Director of Experimental Therapeutics for the Brain Tumor Institute at Children's National Hospital and Associate Professor of Pediatrics at the George Washington School of Medicine and Health Sciences
Dr. Kilburn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
111 Michigan Ave NW
Center for Cancer and Blood disorders
Washington, DC 20010Phone+1 202-476-2800- Is this information wrong?
Summary
- I am board certified in pediatric hematology and oncology as well as clinical pharmacology. I care for children with newly diagnosed and recurrent brain and spinal cord tumors. My research focuses on the development and translation of new therapies for children with brain tumors with a particular focus on novel therapies for glioma and medulloblastoma and combination therapies with focused ultrasound.
Education & Training
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2004 - 2007
Eastern Virginia Medical SchoolResidency, Pediatrics, 2001 - 2004- Eastern Virginia Medical SchoolClass of 2001
Certifications & Licensure
DC State Medical License 2010 - 2024
TX State Medical License 2007 - 2011
VA State Medical License 2001 - 2004- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System Start of enrollment: 2009 Feb 25
- PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Start of enrollment: 2012 Dec 13
- Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Start of enrollment: 2015 Jul 14
- Join now to see all
Publications & Presentations
PubMed
- PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.Kilburn, L. B., Kilburn, L. B., Ryan J Duchatel, Evangeline R Jackson, Sarah G Parackal, Dylan Kiltschewskij, Izac J Findlay, Abdul Mannan, Dilana E Staudt, Bryce C Th...> ;The Journal of Clinical Investigation. 2024 Feb 6
- 4 citationsPhase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).Michelle Monje, Tabitha Cooney, John Glod, Jie Huang, Cody J Peer, Damien Faury, Patricia Baxter, Kim Kramer, Alicia Lenzen, Nathan J Robison, Lindsay Kilburn, Anna Vi...> ;Neuro-Oncology. 2023 Dec 8
- 2 citationsFirst-in-human sonodynamic therapy with ALA for pediatric diffuse intrinsic pontine glioma: a phase 1/2 study using low-intensity focused ultrasound : Technical commun...Adriana Fonseca, Javad Nazarian, Chima Oluigbo, John S Myseros, Roger J Packer, Robert F Keating, Kilburn, L. B., Lindsay Kilburn, Hasan R Syed> ;Journal of Neuro-Oncology. 2023 Apr 1
- Join now to see all
Journal Articles
- Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid BiopsyEugene I Hwang, Cassie Kline, Soonmee Cha, Michael Prados, Lindsay B Kilburn, Nalin Gupta, Roger J Packer, Suresh N Magge, Clinical Cancer Research
Press Mentions
- SonALAsense Forges Ahead with First Patient Dosing for Devastating Childhood Brain CancerSeptember 13th, 2022
“Liquid Biopsies” Could Track Diffuse Midline GliomasAugust 21st, 2019
Professional Memberships
- Member
- Society of Neuro-OncologyMember
Hospital Affiliations
Children's National HospitalWashington, District of Columbia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
